World Journal of Surgical Oncology · 2006 · 31 citations · 12 references
MedicineOncologySurgeryMetastasisOncologic SurgerySurgical OncologyCancer StagingCancer Survival AnalysisMalignant NeoplasmsMalignant TumorsPancreatic CancerPancreatic SurgeryMalignant AscitesMetastatic Pancreatic CancerPancreatic AscitesPancreatic Cancer ResectionPancreatic MetastasesSurgical Management Of AscitesTumor Size Prognosis
BACKGROUND: The purpose of this study was to determine risk factors for development of malignant ascites and its prognostic significance in patients with pancreatic cancer. METHODS: A prospective database was queried to identify patients with pancreatic cancer who develop ascites. Stage at presentation, size, and location of primary tumor, treatment received and length of survival after onset of ascites were determined. RESULTS: A total of 15 patients were identified. Of which 4 patients (1 stage II, 3 stage III) underwent pancreaticoduodenectomy and manifested with ascites 2, 3, 24 and 47 months after surgery (tumor size 2.9 +/- 1.32 cm). All but one of the remaining 11 patients (tumor size 4.4 +/- 3.38 cm) presented with metastatic disease, and all developed malignant ascites 9 months after diagnosis, dying 2 months later. Resected patients lived longer before the onset of ascites, but not after. CONCLUSION: Once diagnosed, ascites in pancreatic cancer patients heralds imminent death. Limited survival should be considered when determining the aggressiveness of further intervention.
12
Ahmedin Jemal, Thomas S. Murray, Alicia Samuels et al. · CA A Cancer Journal for Clinicians · 2003 · 3.3K citations · Full text
Medicine, Demography, Oncology +17
Jennifer Almond, K. H. Link, H. G. Beger et al. · The Lancet · 2001 · 1.1K citations
Yi Feng, Wen-sheng Jin, Debing Xiang et al. · Hepatogastroenterology · 2011 · 524 citations
Ascitic fluid analysis in malignancy-related ascites
Bruce A. Runyon, John C. Hoefs, Timothy R. Morgan · Hepatology · 1988 · 361 citations · Full text